Anteris Technologies Global Corp (ASX: AVR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Anteris Technologies Global Corp Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $189.20 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 36.69 million
Earnings per share -5.050
Dividend per share N/A
Year To Date Return -53.26%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Anteris Technologies Global Corp (ASX: AVR)
    Latest News

    a woman
    Share Fallers

    Insider share buying can't stop the Starpharma share price sliding again today

    The Starpharma Ltd (ASX:SPL) share price is falling again today after a shock FDA rejection.

    Read more »

    a woman
    Share Fallers

    Why the Biotron Limited share price cratered today

    Biotron Limited (ASX:BIT) is working on a treatment that could help cure HIV patients.

    Read more »

    a woman
    Share Fallers

    Why these 4 ASX shares are sinking lower today

    The Paradigm Biopharmaceuticals Ltd (ASX:PAR) share price is one of four sinking lower on the ASX on Wednesday. Here's what…

    Read more »

    a woman
    ⏸️ Investing

    Why these 3 small cap shares are storming higher today

    The Cann Group Ltd (ASX:CAN) share price is one of three at the small end of the market storming higher…

    Read more »

    a woman
    ⏸️ Investing

    Admedus Ltd delivers another big loss

    Admedus Ltd (ASX:AHZ) lost $12.7 million last financial year.

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares sank into the red today

    The BlueScope Steel Limited (ASX:BSL) share price is one of four in the red today. Here’s what you need to…

    Read more »

    a woman
    ⏸️ Investing

    Admedus Ltd reports: Is it a buy at this share price?

    The Admedus Ltd (ASX:AHZ) share price has continued to disappoint.

    Read more »

    a woman
    ⏸️ Investing

    Why the Admedus Ltd share price went nuts today

    In early afternoon trade the shares of Admedus Ltd (ASX:AHZ) are higher by 7.5% following positive news regarding its review.…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 shares are getting crushed today

    The S&P/ASX 200 (Index: ^AXJO) (ASX:XJO) might be rebounding today, but these four shares haven't been so lucky.

    Read more »

    a woman
    ⏸️ Investing

    Here's why these 4 ASX shares jumped higher today

    The S&P/ASX 200 (Index:^AXJO) (ASX:XJO) may have dropped lower today, but that hasn’t stopped Admedus Ltd (ASX:AHZ) and three other…

    Read more »

    a woman
    ⏸️ Investing

    Here's why Admedus Ltd shares have rocketed 54% higher today

    Healthcare company Admedus Ltd (ASX:AHZ) shares have rocketed higher by 54% today. Should you buy?

    Read more »

    a woman
    ⏸️ Investing

    Here's why these 4 ASX shares are soaring today

    The S&P/ASX 200 (Index:^AXJO) (ASX:XJO) may be lower, but that hasn’t stopped SAI Global Limited (ASX:SAI) and three other shares…

    Read more »

    AVR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Anteris Technologies Global Corp

    Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells ADAPT & DurAVR regenerative tissue products, and researches and develops regenerative medicine and immunotherapies. The company was founded on June 23, 1999 and is headquartered in Toowong, Australia.

    AVR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Dec 2024 $8.95 $-0.09 -1.00% 10,790 $9.00 $9.00 $8.82
    19 Dec 2024 $9.04 $0.45 5.24% 18,645 $8.60 $9.15 $8.60
    18 Dec 2024 $8.59 $-0.27 -3.05% 11,647 $8.93 $9.12 $8.50
    17 Dec 2024 $8.86 $-1.68 -15.94% 9,855 $9.40 $9.40 $8.67
    05 Dec 2024 $10.54 $0.54 5.40% 53,355 $10.20 $11.00 $10.00
    04 Dec 2024 $10.00 $0.10 1.01% 15,764 $10.00 $10.15 $9.71
    03 Dec 2024 $9.90 $-0.10 -1.00% 72,720 $10.00 $10.13 $9.50
    02 Dec 2024 $10.00 $-0.13 -1.28% 53,640 $10.18 $10.19 $9.58
    29 Nov 2024 $10.13 $0.23 2.32% 51,120 $9.80 $10.45 $9.80
    28 Nov 2024 $9.90 $0.40 4.21% 45,706 $9.65 $9.90 $9.40
    27 Nov 2024 $9.50 $0.01 0.11% 43,098 $9.50 $9.65 $9.20
    26 Nov 2024 $9.49 $0.14 1.50% 17,925 $9.55 $9.76 $9.23
    25 Nov 2024 $9.35 $0.05 0.54% 13,628 $9.76 $9.79 $9.12

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    19 Jun 2024 Stephen (Steve) Denaro Issued 50,000 $950,000
    Issue of options.
    19 Jun 2024 Wayne Paterson Issued 300,000 $5,700,000
    Issue of options.
    19 Jun 2024 John Seaberg Issued 75,000 $1,425,000
    Issue of options.
    19 Jun 2024 Wenyi Gu Issued 50,000 $950,000
    Issue of options.
    22 Mar 2024 Wayne Paterson Cancelled 117,000 $2,683,980
    Cancellation of securities.
    22 Mar 2024 Stephen (Steve) Denaro Cancelled 8,500 $194,990
    Cancellation of securities.
    22 Mar 2024 John Seaberg Cancelled 20,000 $458,800
    Cancellation of securities.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Stephen (Steve) Denaro Company SecretaryNon-Executive Director Oct 2018
    Mr. Denaro has been providing company secretarial services to other ASX-listed companies since 1994 and serves as a director and sole shareholder of Trio Business Intermediaries Pty Ltd, a business consulting company, specialising in restructuring, corporate governance, directorship and company secretarial services, through which he provides these and other services. Mr. Denaro has over 25 years of experience in mergers and acquisitions, business valuations, accountancy services, and income tax compliance gained from positions as Company Secretary and Chief Financial Officer of public companies and with chartered accountancy firms in Australia and the United Kingdom. He is chair of risk management committee.
    Mr John Seaberg Non-Executive DirectorNon-Executive Chairman Oct 2014
    Mr. Seaberg has been serving as Board Chair of Preceptis Medical Inc since 2016 and Phraxis Medical Inc since 2009. He was Executive VP at Cedar Point Capital, a broker-dealer focused on healthcare investment from June 2015 through December 31, 2023. From 2008 until 2012, Mr. Seaberg was Chair of Synovis Inc., a NASDAQ-listed manufacturer of medical device and bio scaffold tissue products which was acquired by Baxter, and, from 2007 until 2014, was Co-Founder, Chair and Chief Executive Officer of NeoChord Inc., a company commercialising technology developed at the Mayo Clinic for repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr. Seaberg served at Guidant Corp. (subsequently acquired by Boston Scientific Corp.) where he held executive level positions, including Director of Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In addition, Mr. Seaberg was co-Founder, President and Chief Executive Officer of ACIST Medical, from 1991 to 1995. He is member of risk management committee.
    Mr Wayne Paterson Managing DirectorChief Executive Officer Feb 2016
    Mr. Paterson held senior positions at Merck KGaA (Merck), a science and technology company, from 2005 to 2013, including as President of Europe, Canada and Australia, President of Emerging Markets, President of Japan and President of Cardiovascular Medicine. From 1999 until 2005, Mr. Paterson served at Roche Pharmaceuticals, a multinational healthcare company, in several senior positions, including as Head of Pharmaceuticals in Roche's South Korean operation and Head of Commercial Operations for Roche China.
    Dr Wenyi Gu Non-Executive Director Oct 2018
    Dr. Gu is currently guest professor with several Chinese institutes and universities. Since January 2017, Dr. Gu has been working as a Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland. In addition, from April 2021 to March 2023, Dr. Gu was the Chief Scientific Officer of Guangzhou Gillion Biotherapeutics Ltd, a biotechnology company. From 2006 to 2009, he held a Perter Doherty Fellowship and was supported by the National Health and Medical Research Council to work at Harvard Medical School as a visiting research fellow. Dr Gu is member of risk management committee.
    Matthew McDonnell Chief Financial Officer
    -
    David St Denis Chief Operating Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited A/C 2 3,441,479 19.02%
    Perceptive Life Sciences Master Fund Ltd 1,840,000 10.17%
    Citicorp Nominees Pty Limited 1,476,367 8.16%
    HSBC Custody Nominees (Australia) Limited 546,699 3.02%
    Evolution Capital Advisors Pty Ltd 486,387 2.69%
    Hsbc Custody Nominees (Australia) Limited <Gsco Customers A/C> 407,505 2.25%
    Mr Ricky Steven Neumann 380,270 2.10%
    Mr Patrick Chew 343,355 1.90%
    BNP Paribas Nominees Pty Ltd <IB Au Noms Retailclient> 325,076 1.80%
    Mutual Trust Pty Ltd 271,411 1.50%
    Ltl Capital Pty Ltd 266,761 1.47%
    Bnp Paribas Noms Pty Ltd <Global Markets> 261,779 1.45%
    Mishtalem Pty Ltd 211,500 1.17%
    Ubs Nominees Pty Ltd 176,988 0.98%
    BNP Paribas Noms Pty Ltd 176,560 0.98%
    Amedan Pty Ltd 175,000 0.97%
    Merrill Lynch (Australia) Nominees Pty Limited 159,297 0.88%
    Mr David Lamm 125,000 0.69%
    Dr Gary Owen Rooke 115,000 0.64%
    Hsbc Custody Nominees (Australia) Limited Gsco Eca 113,540 0.63%

    Profile

    since

    Note